Aventis Lovenox Claims “False”; Corrective Ads Not Needed, Court Rules
Executive Summary
Aventis does not have to run corrective advertisements for two Lovenox marketing claims that were false but have since been discontinued, a federal judge ruled April 29
You may also be interested in...
Aventis Lovenox Promotions Challenged By Coagulation Test Maker
A diagnostics company that developed a coagulation test for use with Lovenox alleges Aventis is falsely promoting the antithrombotic as requiring "no routine monitoring" and being "therapeutic from dose one.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials